Genprex, Inc. (GNPX)
3.48
-0.06
(-1.69%)
USD |
NASDAQ |
Sep 09, 11:40
Genprex Total Liabilities (Quarterly) : 2.342M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.342M |
| March 31, 2026 | 3.376M |
| December 31, 2025 | 2.197M |
| September 30, 2025 | 2.795M |
| June 30, 2025 | 2.436M |
| March 31, 2025 | 2.142M |
| December 31, 2024 | 2.504M |
| September 30, 2024 | 2.242M |
| June 30, 2024 | 2.259M |
| March 31, 2024 | 3.808M |
| December 31, 2023 | 3.254M |
| September 30, 2023 | 4.338M |
| June 30, 2023 | 3.860M |
| March 31, 2023 | 4.835M |
| December 31, 2022 | 2.810M |
| September 30, 2022 | 2.457M |
| June 30, 2022 | 2.154M |
| March 31, 2022 | 2.385M |
| December 31, 2021 | 1.585M |
| September 30, 2021 | 1.162M |
| Date | Value |
|---|---|
| June 30, 2021 | 1.047M |
| March 31, 2021 | 0.6136M |
| December 31, 2020 | 0.4507M |
| September 30, 2020 | 0.3757M |
| June 30, 2020 | 0.2398M |
| March 31, 2020 | 0.6972M |
| December 31, 2019 | 0.5107M |
| September 30, 2019 | 0.5372M |
| June 30, 2019 | 0.9388M |
| March 31, 2019 | 0.2311M |
| December 31, 2018 | 0.3878M |
| September 30, 2018 | 0.5654M |
| June 30, 2018 | 0.3005M |
| March 31, 2018 | 1.428M |
| December 31, 2017 | 0.831M |
| September 30, 2017 | 0.3953M |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | 0.2857M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
| Vericel Corp. | 132.82M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 17.14M |
| Shareholders Equity (Quarterly) | 14.80M |
| Current Ratio | 6.765 |